Confronto

BPC-157 vs. KPV

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Guarigione

N. CAS

137525-51-0

67727-97-3

Peso molecolare

1419.5 g/mol

342.4 g/mol

Emivita

4 h

nessun dato

Sequenza

GEPPPGKPADDAGLV

KPV

Meccanismo d'azione

BPC-157

Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.

KPV

KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.

Base di evidenze

Evidenza più alta

Modello animale

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	BPC-157	KPV
Australia	Vietato	—
Svizzera	Non approvato	—
Germania	Non approvato	Non approvato
Stati Uniti	Solo ricerca	Solo ricerca

Voci complete

Frequently asked questions

What is the difference between BPC-157 and KPV?: BPC-157 is classified as "Guarigione", while KPV is classified as "Guarigione". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, BPC-157 or KPV?: The highest available evidence level is "Modello animale" for BPC-157 and "Modello animale" for KPV. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of BPC-157 and KPV in Germany and the United States?: Germania: BPC-157 — Non approvato, KPV — Non approvato. Stati Uniti: BPC-157 — Solo ricerca, KPV — Solo ricerca. These are factual summaries with source and review date on the individual pages.

Country

BPC-157

KPV

Australia

Vietato

—

Svizzera

Non approvato

—

Germania

Non approvato

Stati Uniti

Solo ricerca

Frequently asked questions

What is the difference between BPC-157 and KPV?

BPC-157 is classified as "Guarigione", while KPV is classified as "Guarigione". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, BPC-157 or KPV?

The highest available evidence level is "Modello animale" for BPC-157 and "Modello animale" for KPV. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of BPC-157 and KPV in Germany and the United States?

Germania: BPC-157 — Non approvato, KPV — Non approvato. Stati Uniti: BPC-157 — Solo ricerca, KPV — Solo ricerca. These are factual summaries with source and review date on the individual pages.